Bonk (NASDAQ:BNKK) Director Mitchell Austin Rudy Purchases 7,500 Shares of Stock

Bonk, Inc. (NASDAQ:BNKK) Director Mitchell Austin Rudy bought 7,500 shares of Bonk stock in a transaction dated Monday, June 22nd. The stock was acquired at an average cost of $1.56 per share, with a total value of $11,700.00. Following the transaction, the director owned 73,341 shares of the company’s stock, valued at $114,411.96. This trade represents a 11.39% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mitchell Austin Rudy also recently made the following trade(s):

• On Tuesday, June 16th, Mitchell Austin Rudy purchased 2,500 shares of Bonk stock. The stock was acquired at an average price of $1.32 per share, for a total transaction of $3,300.00.
• On Wednesday, June 10th, Mitchell Austin Rudy purchased 12,000 shares of Bonk stock. The shares were acquired at an average cost of $1.37 per share, for a total transaction of $16,440.00.
• On Thursday, April 9th, Mitchell Austin Rudy acquired 31,055 shares of Bonk stock. The stock was acquired at an average price of $2.82 per share, with a total value of $87,575.10.

Bonk Price Performance

NASDAQ BNKK opened at $1.54 on Wednesday. The company has a market capitalization of $12.32 million, a P/E ratio of -0.33 and a beta of 1.86. Bonk, Inc. has a 12-month low of $1.25 and a 12-month high of $46.90. The firm has a 50-day moving average price of $2.11 and a two-hundred day moving average price of $3.03.

Bonk (NASDAQ:BNKK) last announced its earnings results on Wednesday, May 13th. The company reported ($0.23) EPS for the quarter. Bonk had a negative return on equity of 148.62% and a negative net margin of 838.37%.The business had revenue of $0.79 million for the quarter.

Wall Street Analysts Forecast Growth

BNKK has been the topic of a number of recent research reports. Wall Street Zen lowered Bonk from a “hold” rating to a “sell” rating in a research note on Sunday. Weiss Ratings downgraded Bonk from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Trading of Bonk

A number of institutional investors and hedge funds have recently made changes to their positions in BNKK. Geode Capital Management LLC bought a new position in Bonk in the fourth quarter valued at approximately $128,000. Steward Partners Investment Advisory LLC bought a new stake in Bonk during the fourth quarter worth $37,000. Jane Street Group LLC bought a new stake in Bonk during the fourth quarter worth $96,000. Finally, State Street Corp acquired a new stake in shares of Bonk in the 4th quarter valued at $33,000. Institutional investors own 12.55% of the company’s stock.

About Bonk

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.